In vivo specificity of human alpha1,3/4-fucosyltransferases III-VII in the biosynthesis of LewisX and Sialyl LewisX motifs on complex-type N-glycans. Coexpression studies from bhk-21 cells together with human beta-trace protein.
Each of the five human alpha1,3/4-fucosyltransferases (FT3 to FT7) has been stably expressed in BHK-21 cells together with human beta-trace protein (beta-TP) as a secretory reporter glycoprotein. In order to study their in vivo properties for the transfer of peripheral Fuc onto N-linked complex-type glycans, detailed structural analysis was performed on the purified glycoprotein. All fucosyltransferases were found to peripherally fucosylate 19-52% of the diantennary beta-TP N-glycans, and all enzymes were capable of synthesizing the sialyl LewisX (sLex) motif. However, each enzyme produced its own characteristic ratio of sLex/Lex antennae as follows: FT7 (only sLex), FT3 (14:1), FT5 (3:1), FT6 (1.1:1), and FT4 (1:7). Fucose transfer onto beta-TP N-glycans was low in FT3 cells (11% of total antennae), whereas the values for FT7, FT5, FT4, and FT6 cells were 21, 25, 35, and 47%, respectively. FT3, FT4, FT5, and FT7 transfer preponderantly one Fuc per diantennary N-glycan. FT4 preferentially synthesizes di-Lex on asialo diantennary N-glycans and mono-Lex with monosialo chains. In contrast, FT6 forms mostly alpha1,3-difucosylated chains with no, one, or two NeuAc residues. FT3, FT4, and FT6 were proteolytically cleaved and released into the culture medium in significant amounts, whereas FT7 and FT5 were found to be largely resistant toward proteolysis. Studies on engineered soluble variants of FT6 indicate that these forms do not significantly contribute to the in vivo fucose transfer activity of the enzyme when expressed at activity levels comparable to those obtained for the wild-type Golgi form of FT6 in the recombinant host cells.
Grabenhorst
E
E
Protein Glycosylation, Gesellschaft für Biotechnologische Forschung mbH, D-38124 Braunschweig, Germany.
Nimtz
M
M
Costa
J
J
Conradt
H S
HS
D000595:Amino Acid Sequence; D000818:Animals; D001609:Beta-Globulins / Q000235:genetics / Q000378:metabolism; D002240:Carbohydrate Sequence; D002478:Cells, Cultured; D006224:Cricetinae; D005647:Fucosyltransferases / Q000235:genetics / Q000378:metabolism*; D006023:Glycoproteins / Q000096:biosynthesis*; D006031:Glycosylation; D006801:Humans; D019746:Intramolecular Oxidoreductases; D007527:Isoenzymes / Q000378:metabolism*; D007983:Lewis Blood Group Antigens / Q000378:metabolism*; D016256:Lewis X Antigen / Q000096:biosynthesis*; D054834:Lipocalins; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000096:biosynthesis*; D011994:Recombinant Proteins / Q000378:metabolism; D000080506:Sialyl Lewis X Antigen; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013379:Substrate Specificity
D001609:Beta-Globulins; D006023:Glycoproteins; D007527:Isoenzymes; D007983:Lewis Blood Group Antigens; D016256:Lewis X Antigen; D054834:Lipocalins; D009844:Oligosaccharides; D011994:Recombinant Proteins; D000080506:Sialyl Lewis X Antigen; D005647:Fucosyltransferases; C019818:3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase; D019746:Intramolecular Oxidoreductases; C022466:prostaglandin R2 D-isomerase